Alternative Therapies (Part 1)

May 2005
PN;May2005, Vol. 59 Issue 5, p26
Trade Publication
The article focuses on treatments for multiple sclerosis (MS). Alternative therapies come from many disciplines and traditions. Alternative treatments may have no clear relation to what medical science knows about the cause of a particular disease or its symptoms. Despite this lack of scientific rationale, alternative medicine appeals to many Americans. Clinical trials are therefore particularly important in establishing the safety and effectiveness of new treatments for MS. MS is a disease famous for spontaneous remissions.


Related Articles

  • Minimal change disease with interferon-beta therapy for relapsing remitting multiple sclerosis. Aravindan, Ananthakrishnapuram; Yong, Jim; Killingsworth, Murray; Suranyi, Michael; Wong, Jeffrey // Nephrology Dialysis Transplantation;Apr2010, Vol. 25 Issue 4, p132 

    Interferon beta is widely used for the treatment of relapsing and remitting multiple sclerosis. Renal side effects including nephrotic syndrome have been increasingly described with interferon beta treatment. We describe an illustrative case of a patient who developed severe nephrotic syndrome...

  • The Placebo Effect. King, Janet Spencer // Inside MS;Oct-Dec2004, Vol. 22 Issue 4, p14 

    Presents information on the use of placebo in clinical trials for multiple sclerosis (MS). Explanation why a placebo is effective; Details of how an inert placebo produces a change in immune system activity; Comparison of placebo and complementary and alternative medicine used for treating MS.

  • Comparison of the effect of two types of acupuncture on quality of life in secondary progressive multiple sclerosis: a preliminary single-blind randomized controlled trial. Donnellan, Clare P.; Shanley, Jackie // Clinical Rehabilitation;Mar2008, Vol. 22 Issue 3, p195 

    Objective: To compare the effect of two types of acupuncture on the quality of life of individuals with secondary progressive multiple sclerosis and provide preliminary evidence regarding the safety of this intervention for this population. Design: Preliminary single-blind randomized controlled...

  • Variants of personality maladaptation in patients with multiple sclerosis. T. Reznikova; I. Terent’eva; G. Kataeva // Neuroscience & Behavioral Physiology;Oct2007, Vol. 37 Issue 8, p747 

    Abstract  A total of 34 patients with multiple sclerosis (MS) aged 14–52 years, with disease onset at age 24.3 � 7.5 years, were studied. Disease severity on the Kurtzke scale (EDSS) was 3.6 � 1.7 points. Seven patients were in exacerbation of MS and 27 were in remission....

  • Searching for Comfort. Vanerbilt, Shirley // Massage & Bodywork;Aug/Sep2004, Vol. 19 Issue 4, p50 

    Focuses on the alternative therapies for multiple sclerosis (MS). Association of non-traumatic stressful events with increased risk for MS; Details on the conventional medical treatment for MS; Use of a complementary and alternative medicine to improve health and for symptom management. INSETS:...

  • news.  // Inside MS;Apr-Jun2004, Vol. 22 Issue 2, p32 

    Presents news briefs on multiple sclerosis (MS) as of April 2004. Link between smoking and MS according to a study in Norway; Details of a Web-based survey completed by the Complementary and Alternative Medicine Program at the Rocky Mountain MS Center.

  • Five to ten years survivors of patients with advanced cancers after chemotherapy with traditional Chinese medicine. Geogre Zhu // Journal of Chinese Clinical Medicine;2009, Vol. 4 Issue 9, p512 

    The article presents a study on the significant application of chemotherapy and traditional Chinese medicine for the treatment of patients with advanced cancers under remission. The study, which was conducted on 65 patients treated with different dosages of chemotherapy conjoined with Chinese...

  • Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. Norian, Lyse A.; James, Britnie R.; Griffith, Thomas S. // Cancers;2011, Vol. 3 Issue 1, p603 

    Numerous biologic approaches are being investigated as anti-cancer therapies in an attempt to induce tumor regression while circumventing the toxic side effects associated with standard chemo- or radiotherapies. Among these, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has...

  • Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. Coyle, Patricia K.; Cohen, Bruce A.; Leist, Thomas; Markowitz, Clyde; Oleen-Burkey, MerriKay; Schwartz, Marc; Tullman, Mark J.; Zwibel, Howard // BMC Neurology;2014, Vol. 14 Issue 1, p1 

    Background: Data sources for MS research are numerous but rarely provide an objective measure of drug therapy compliance coupled with patient-reported health outcomes. The objective of this paper is to describe the methods and baseline characteristics of the Therapy Optimization in MS (TOP MS)...

  • Potentials and limitations of current and emerging immunotherapies. Zettl, Uwe K.; Mix, Eilhard // Journal of Neurology;Dec2008 Supplement 6, Vol. 255, p1 

    The authors reflect on the potential of immunotherapies. They assert that immunotherapies have played an increasing role for the treatment of neurological diseases in clinical practice. They reveal that it is especially used for the treatment of multiple sclerosis (MS), which represents the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics